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Abstract: 
 
Calmodulin (CaM) plays a central role in regulating a myriad of cellular functions in 
physiological and pathophysiological processes, thus representing an important drug target. In 
previous reviews, our group has reported relevant information regarding natural anti-CaM 
compounds up to 2009. Natural sources continue to provide a diverse and unique reservoir of 
CaM inhibitors for drug and research tool discovery. This review provides an update of natural 
products with reported CaM inhibitory properties, which includes around 70 natural products and 
some synthetic analogues, belonging to different structural classes. Most of these natural 
inhibitors were isolated from fungi and plants and belong to the stilbenoid, polyketide, alkaloid, 
and peptide structural classes. These products were discovered mainly using a fluorescence-
based method on rationally designed biosensors, which are highly specific, low-cost, and 
selective and have short reaction times. The effect of several antimitotic drugs on Ca2+-hCaM is 
also described. 
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Article: 
 
Introduction 
 
Calmodulin (CaM) is the most important intracellular Ca2+-binding protein in eukaryotic 
organisms. From the structural point of view, it is a small protein with only 148 amino acid 
residues arranged in two globular domains (N- and C-terminals), each one with two Ca2+-binding 
sites. Both domains are connected by a flexible linker, which is involved in the interactions of 
CaM with its target proteins and antagonists.(1) CaM plays a central role in regulating a myriad 
of cellular functions in physiological and pathophysiological processes. Thus, CaM is involved 
in cell motility, cytoskeleton architecture and function, cell proliferation, apoptosis, autophagy, 
metabolic homeostasis, phosphorylation/dephosphorylation of proteins, ion channel function, 
reproductive processes, smooth muscle contraction–relaxation, and gene expression, to mention 
a few. CaM controls all these events through the modulation of more than 100 different proteins 
including enzymes such as calmodulin-dependent phosphodiesterase (PDE1), nitric oxide 
synthases (NOS), several kinases, ion channels, and phosphatases, among others. Moreover, 
CaM has been associated with several pathological conditions including unregulated cell growth 
and smooth muscle malfunctions.(2) For example, recent findings have shown that most types of 
cancer are associated with elevated levels of Ca2+-bound CaM (Ca2+-CaM) and that some of its 
antagonists inhibit tumor cell invasion in vitro and metastasis in vivo.(2) As a consequence, this 
protein represents a potential drug target, and those agents that interfere with its modulatory 
properties can be considered CaM antagonists, which are also valuable tools for the study of 
physiological processes where the protein is involved. 
 
A few structurally diverse natural products are CaM antagonists or inhibitors of the complexes 
this protein forms with its target enzymes. These products have been isolated from a wide variety 
of organisms from the Fungi, Animalia, Protista, and Plantae kingdoms. In previous reviews our 
group has reported the most relevant information regarding anti-CaM compounds from natural 
sources up to 2009.(3, 4) Herein, this information has been updated, emphasizing our own work. 
 
Assays for Discovering CaM Inhibitors 
 
CaM antagonists have been detected by several methods. The most widely used include 
functional enzymatic assays (FEA),(5, 6) gel electrophoresis,(7) affinity chromatography,(7, 
8) site-directed mutagenesis,(9) X-ray crystallography,(10, 11) circular dichroism,(8) nuclear 
magnetic resonance spectroscopy,(12, 13) small-angle neutron scattering,(14, 15) isothermal 
titration calorimetry,(16, 17) localized surface plasmon resonance,(18) dual polarization 
interferometry,(19) intensity-fading matrix-assisted laser desorption/ionization mass 
spectrometry (IF-MALDI-MS),(20) and fluorescence-based methods including bioengineered 
biosensors.(21-26) The fluorescence-based methods are highly specific, low-cost, and selective 
and have short reaction times. In our studies, we have employed FEA with PDE1 as reporter 
enzyme, gel electrophoresis, and fluorescent biological sensors built with human CaM (hCaM). 
Our devices have been produced in Escherichia coli BL21-AI and engineered by rational design, 
replacing methionine, leucine, valine, or threonine in different positions by cysteine using site-
directed mutagenesis; the resulting proteins were purified by hydrophobic exchange 
chromatography.(24-26) Thereafter, a thiol reactive fluorophore [i.e., monobromobimane 
(mBBr) or Alexa Fluor 350 (AF350)] was covalently attached to the cysteine residue as a 
fluorescent probe (Scheme 1). With these molecular tools it has been possible to correlate the 
conformational changes upon ligand binding to CaM with the changes in the emission properties 
of the labeled protein. Biosensor hCaM M124C-mBBr was built initially because the 
microenvironment surrounding methionine 124 is very susceptible to classical CaM inhibitors 
such as chlorpromazine (CPZ) and trifluorperazine (TFP).(24) Afterward, other devices were 
built including hCaM L39C-mBBr/V91C-mBBr,(25)hCaM M124C-AF350,(26)hCaM V91C-
mBBr,(27) and hCaM T110C-mBBr.(28) The hCaM L39C-mBBr/V91C-mBBr is suitable for 
detecting classical and nonclassical inhibitors of CaM because the labeled recognition 
fluorophores are strategically located, and upon any ligand binding, quenching of the 
fluorescence will always be detected. Biosensor hCaM T110C-mBBr is appropriated for testing 
nonclassical inhibitors since the fluorophore probe is located at the flexible linker, far from sites 
where TFP interacts. Finally, hCaM M124C-AF350 was designed as an alternative to detect 
colorful classical CaM inhibitors without interfering with the response of the biosensor. 
Measurements with all these biosensors are carried out in solution, quantitatively or qualitatively, 
as well as with high sensitivity and specificity. 
 
Scheme 1 
 
 
Chart 1 
 
 
Stilbenoids from Select Orchids 
 
As part of our program to demonstrate the preclinical efficacy of selected Mexican medicinal 
plants, it was demonstrated that the extracts from the orchids Scaphyglottis livida (Lindl.) 
Schltr., Maxillaria densa Lindl., and Nidema boothi (Lindl.) Schltr. induced relaxation of the 
spontaneous contractions of the guinea-pig or rat ilea using ex vivo models. The IC50 values of 
these extracts ranged from 0.62 to 6 μg/mL, with maxima effects up to 90%.(29-32) Bioassay-
guided fractionation of the active extracts allowed the isolation of a few bioactive bibenzyls and 
phenanthrenes. These metabolites also inhibited the spontaneous contractions of the isolated rat 
or guinea-pig ilea in a concentration-dependent form with IC50 values ranging from 0.33 to 7 
μM.(4, 29-31) The studies conducted to determine their smooth muscle-relaxant mechanism 
revealed that their effects did not involve a direct interaction on the receptors of common 
transmitters nor any interference with Ca2+ influx in the cell.(29-32) However, functional assays 
and radioimmunoassays demonstrated that the bibenzyl compounds exerted smooth muscle-
relaxant activity by the release of NO via an increase of cGMP levels in the rat ileum.(29) In the 
case of the phenanthrenes, a Ca2+ channel blockade partially accounted for their pharmacological 
effect.(33) 
 
 
Figure 1. Fluorescence spectra and titration curves of the complexes Ca2+-hCaM M124C-
AF350 with (A) gigantol (1), (B) gymnopusin (8), and (C) CPZ. The absolute changes of maximal 
fluorescence emission were corrected for light-scattering effects and plotted relative changes in 
intensity (ΔΔIF) against the ligand to total protein–inhibitor complex ratio (insets). 
 
The contraction–relaxation processes go around phosphorylation–dephosphorylation of the 
myosin light chain (MLC), and the equilibrium is controlled by a complex cell signaling cascade 
where CaM plays a central role.(34) Thus, upon any contractile stimulus, Ca2+ enters the cell and 
binds to CaM; the complex Ca2+-CaM activates the myosin light chain kinase (MLCK), which in 
turn phosphorylates MLC, triggering smooth muscle contraction. On the other hand, smooth 
muscle relaxation occurs either as a result of removal of the contractile stimulus or by a direct 
action of a substance that stimulates inhibition of the contractile mechanisms, and regardless, the 
process of relaxation requires a decrease of intracellular Ca2+ and an increase of MLC 
phosphatase activity.(34) Thus, on the basis of these considerations, the effects of the stilbenoids 
(Chart 1) on Ca2+-CaM were also investigated. In the electrophoresis assay, Ca2+-CaM treated 
with these compounds had a lower electrophoretic mobility than the untreated protein.(31) In the 
functional enzymatic assays, the isolated stilbenoids inhibited the activity of the complex Ca2+-
CaM-PDE1 with IC50 values ranging from 3.2 to 36.6 μM, which was similar to the action of 
CPZ (IC50 = 10.3 μM).(31) More recently, we found that bibenzyls 1 and 2 and phenanthrenes 3–
8 quenched the extrinsic fluorescence of the biosensors hCaM M124C-AF350 or hCaM M124C-
mBBr (Table 1). The fluorescence changes were monitored between 450 and 550 nm. In all 
cases, the fluorescence intensity changed with increasing concentrations of the compounds. 
These spectroscopic changes were attributed to the formation of Ca2+-hCaM-tested compound 
complexes; the phenanthrenes showed the highest affinity. For example, Figure 1 illustrates the 
effect provoked by gigantol (1), gymnopusin (8), and CPZ. The Kd (dissociation constant) values 
were 60, 0.19, and 1.0 μM, respectively. Thus, the bibenzyls and phenanthrenes of the medicinal 
orchids are, unequivocally, Ca2+-CaM antagonists, and this effect may be related with their 
spasmolytic action. 
 
Table 1. Calmodulin Inhibitors Obtained from Selected Fungi and Plants and by Synthesis As 
Detected by Fluorescence-Based Methods Using hCaM M124C-mBBr, hCaM L39C-
mBBr/V91C-mBBr, hCaM M124C-AF350, hCaM V91C-mBBr, and hCaM T110C-
mBBr Biosensors and Docking Analysis 
compound Kda (μM) Kib (μM) source ref(s) 
gigantol (1) 60.8 37.0 S. livida, N. boothi 29, 31 
ephemerantol B (3) 1.1 565.0 N. boothi, M. densa 30, 31 
erianthridin (4) 1.4 160.0 M. densa 30 
2,5-dihydroxy-3,4-dimethoxyphenanthrene (5) 2.2 22.1 S. livida, M. densa 29, 30 
fimbriol-A (6) 1.7 65.4 M. densa 30 
nudol (7) 1.5 42.8 M. densa 30 
gymnopusin (8) 0.19 275.0 M. densa 30 
3-methoxy-5-[2-(4-methoxyphenyl)ethyl]phenol (9) 80.0 109.7 synthesis 35 
4-[2-(3,5-dimethoxyphenyl)ethyl]-1-ethoxy-2-methoxybenzene (10) 9.9 85.3 synthesis 35 
3-{2-[4-(dimethylamino)phenyl]ethyl}-5-methoxyphenol (11) 12.0 98.1 synthesis 35 
N-{4-[2-(3,5-dimethoxyphenyl)ethyl]phenyl}-N,N-dimethylamine (12) 10.0 100.1 synthesis 35 
1,3-dimethoxy-5-[2-(4-methoxyphenyl)ethyl]benzene (13) 21.8 88.9 synthesis 35 
3-[2-(4-ethoxy-3-methoxyphenyl)ethyl]phenol (14) 58.1 109.7 synthesis 35 
3-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-5-methoxyphenol (15) 25.3 124.2 synthesis 35 
diphenylethane (16) NBc 113.4 synthesis 35 
3-[2-(1,3-benzodioxol-5-yl)ethyl]-5-methoxyphenol (17) 45.5 35.2 synthesis 35 
3-[2-(1,3-benzodioxol-5-yl)ethyl]phenol (18) 63.8 13.8 synthesis 35 
(2E)-1-(4-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (19) 10.3 16.2 synthesis 35 
(2E)-3-(3-hydroxy-4-methoxyphenyl)-1-(3-hydroxy-5-methoxyphenyl)prop-2-en-1-one (20) 3.9 35.6 synthesis 35 
(2E)-1-(3-hydroxy-5-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one (21) 5.3 23.7 synthesis 35 
compound Kda (μM) Kib (μM) source ref(s) 
(2E)-3-(1,3-benzodioxol-5-yl)-1-(3-hydroxyphenyl)prop-2-en-1-one (22) NDd 13.5 synthesis 35 
4-[3-(4-methoxyphenyl)propyl]phenol (23) 8.7 36.8 synthesis 35 
4-[3-(1,3-benzodioxol-5-yl)propyl]phenol (24) 14.2 27.1 synthesis 35 
4-[3-(3-hydroxy-5-methoxyphenyl)propyl]-2-methoxyphenol (25) 54.3 88.7 synthesis 35 
2-(3,5-dimethoxybenzyl)-6-methoxyphenol (26) 33.8 116.8 synthesis 35 
4-(3,5-dimethoxybenzyl)-2-methoxyphenol (27) 33.1 80.0 synthesis 35 
diphenylmethane (28) NBc 73.5 synthesis 45 
malbrancheamide (29) 1.1 0.20 M. aurantiaca 39, 41 
malbrancheamide B (30) 4.8 0.50 M. aurantiaca 41 
isomalbrancheamide B (31) 4.8 0.50 M. aurantiaca 41 
15-chlorotajixanthone (33) 0.03 NDd Emericella sp. 25379 25, 43 
14-methoxytajixanthone (34) 4 × 10–3 0.03 Emericella sp. 25379 25, 43 
shamixanthone (35) 0.24 0.08 Emericella sp. 25379 25, 43 
tajixanthone hydrate (36) 0.09 8 × 10–3 Emericella sp. 25379 25, 43 
15-acetyltajixanthone hydrate (37) 0.50 3 × 10–3 Emericella sp. 25379 25, 43 
16-chlorotajixanthone (38) 7.3 0.08 Emericella sp. 25379 25, 43 
tajixanthone (39) 4 × 10–3 0.05 Emericella sp. 25379 25, 43 
emericellin (40) 7 × 10–3 0.14 Emericella sp. 25379 25, 43 
variecoxanthone A acetate (41) 0.12 0.28 Emericella sp. 25379 25, 43 
acremoxanthone C (42) 0.02 0.41 P. lilacinum 28 
acremonidin A (43) 0.02 0.37 P. lilacinum 28 
vermelhotin (44) 0.25 168.0 endophyte MEXU 26346 46 
5-hydroxy-2,7-dimethoxy-8-methylnaphthoquinone (45) 1.6 NDd S. minimoides 27 
emodin (46) 0.33 4.7 A. stromatoides 47 
ω-hydroxyemodin (47) 0.76 5.3 A. stromatoides 47 
(2S,3S)-5-hydroxy-6,8-dimethoxy- 2,3-dimethyl-4H-2,3-dihydronaphtho[2,3-b]-pyran-4-one (48) 0.22 34.9 G. polythrix 49, 50 
(2S,3S)-5-hydroxy-6,8,10-trimethoxy-2,3-dimethyl-4H-2,3-dihydronaphtho[2,3-b]-pyran-4-one (49) 0.39 13.5 G. polythrix 49, 50 
(2S)-5-hydroxy-6,8- dimethoxy-2-methyl-4H-2,3-dihydronaphtho[2,3-b]-pyran-4-one (50) 2.2 52.1 G. polythrix 49, 50 
(2S)-5-hydroxy-6,8,10-trimethoxy-2-methyl-4H-2,3-dihydronaphtho[2,3-b]-pyran-4-one (51) NBc NDd G. polythrix 49, 50 
5-hydroxy-6,8-dimethoxy-2,3-dimethyl-4H-naphtho[2,3-b]-pyran-4-one (52) 1.4 50.6 G. polythrix 49, 50 
rubrofusarin B (53) NBc NDd G. polythrix 49, 50 
chaetomine (54) 0.06 1.8 C. globosum 
 
beauverolide C (55) 0.30 1.4 I. fumosorosea 52 
beauverolide F (56) 0.40 0.63 I. fumosorosea 52 
beauverolide I (57) 0.19 9.7 I. fumosorosea 52 
beauverolide Ja (58) 0.08 0.39 I. fumosorosea 52 
beauverolide L (59) 1.7 1.1 I. fumosorosea 52 
beauverolide M (60) 3.4 9.5 I. fumosorosea 52 
beauverolide N (61) 1.7 5.6 I. fumosorosea 52 
vinblastine 1.7 0.29 Catharanthus roseus 
 
vincristine 0.80 0.02 Catharanthus roseus 
 
colchicine 0.50 18.4 Colchicum autumnale 
 
paclitaxel NBc NBc Taxus brevifolia 
 
griseofulvin NBc NBc P. raistrickii 
 
a Apparent constant from the fluorescence experiments. 
b Calculated inhibition constant from docking results. 
c NB = not binding. 
d ND = not determined. 
 
On the basis of the results above-discussed, more than 20 analogues of 1 were designed and 
synthesized to find more active hCaM antagonists (Chart 1).(35) The gigantol analogues 9–
28 differed not only in the position of the hydroxy and methoxy groups along the bibenzyl core 
but also in the length of the linker chain joining both phenyl moieties. The bibenzyls were 
obtained using the Wittig reaction; the diphenylmethanes were obtained by an acid-catalyzed 
intramolecular rearrangement of a benzyl phenyl ether. Finally, the oxygenated 1,3-
diphenylpropanes were obtained by one-step catalytic reduction of some chalcones in acid and 
10% palladium over carbon, at 60 °C.(35) 
 
The effect of the synthetic analogues 9–28 on the complex Ca2+-hCaM-PDE1 and hCaM 
M124C-mBBr biosensor was also analyzed (Table 1). The synthetic compounds quenched the 
fluorescence of the device to different extents, then revealing different affinities to Ca2+-hCaM; 
their Kd values were in the range 3–80 μM. The most active were those possessing a propyl chain 
between the phenyl rings, inclusive of compounds 20, 21, and 24. Among the bibenzyls, 
compounds 11–13 were the most potent. In general, the position of the oxygenated functions did 
not have a clear impact on the affinity of the compounds to the Ca2+-hCaM complex. 
 
 
Figure 2. Predicted binding mode of (A) gymnopusin (8, blue sticks) and gigantol synthetic 
analogues, (B) 10 (orange sticks), and (C) 20 (yellow sticks), into Ca2+-hCaM (hydrogen bonds 
are shown as green dashed lines). (D) Structural model of Ca2+-hCaM-inhibitor complexes 
represented as gray cartoon (TFP, green lines). Amino acids involved in the interactions are 
shown as cyan sticks. 
 
In order to establish the putative binding mode of the bibenzyls and phenanthrenes to Ca2+-
hCaM, docking studies were performed using the program AUTODOCK 4.0.2.(36, 37) All 
structures were optimized with the program Gaussian 09, using the density functional theory 
method (DFT) at the B3LYP/3-21G level. Initially, the ligands were docked to the entire protein 
(Ca2+-CaM-4TFP, PDB code 1LIN); then, the best conformations were docked in a smaller area 
in order to refine the results. In all cases, the two phenyl groups of the scaffold sink into the 
hydrophobic pockets, establishing hydrophobic and/or π–π interactions with the protein, in a 
similar way to TFP. As examples, docking results for compounds 8, 10, and 20, the most active 
according to the fluorescence assay, are illustrated in Figure 2.(38) 
 
Fungal Metabolites 
 
In our work, fungal microorganisms have yielded the best CaM antagonists, with some of these 
having Kd values in the nM range. To isolate these compounds, we have pursued bioassay-guided 
fractionation of the active fungal extracts. Thus, once the appropriate fermentation conditions 
(solid or liquid media) are established, organic-soluble extracts are prepared and submitted for 
anti-CaM testing using hCaM M124C-AF350 or hCaM M124C-mBBr. The active extracts are 
fractionated until active compounds are isolated. In the next few paragraphs, selected examples 
are described. 
 
Alkaloids from Malbranchea aurantiaca 
 
The malbrancheamides (29–32) (Chart 2) belong to a rare family of prenylated indole alkaloids 
containing a bicyclic diazaoctane moiety. These compounds were isolated from the liquid culture 
(potato-dextrose broth, PDB) of the coprophilous fungus Malbranchea aurantiaca Sigler and 
Carmich (Myxotrichaceae). Initially, the effects of the alkaloids on CaM were assessed by gel 
electrophoresis and the FEA.(39-41) Most of these studies were described in our last 
review.(4) More recently, 29–32 were tested with the hCaM M124C-mBBr biosensor, and only 
malbrancheamide (29) quenched significantly (Kd = 1.1 μM) the fluorescence of the 
device.(41) The monochlorinated derivatives (30 and 31) provoked only limited decreases in 
fluorescence quenching, and premalbrancheamide (32) none. Thus, the presence of two chlorine 
atoms confers to 29 the best affinity to Ca2+-hCaM.(41) 
 
Chart 2 
 
 
Docking analysis predicted that 29 is anchored in the hydrophobic pocket of Ca2+-hCaM through 
hydrogen-bonding and hydrophobic interactions with a few specified amino acids of the 
protein.(41) To map experimentally the hydrophobic interactions in the complex Ca2+-hCaM-29, 
HSQC experiments were performed at different mixing times. Titration of 15N,13C double-
labeled Ca2+-hCaM with a solution of 29 induced a diamagnetic shift of most of the methionine 
methyl resonances (Figure 3). The most significant changes were observed for the methionine 
residues 36, 51, 71, 72, 76, 109, 124, 144, and 145, thereby corroborating the docking 
predictions.(41) 
 
 
Figure 3. HSQC experiments of 15N,13C double-labeled Ca2+-hCaM and after titration with 
malbrancheamide (29). 
 
The excellent CaM inhibitory properties of 29 prompted us to investigate its smooth muscle-
relaxant activity using noradrenaline (NA) precontracted rat aortal rings. The results indicated 
that 29 induced a vasorelaxant effect (EC50 = 2.7 μM) mainly by an endothelium-dependent 
pathway, with maximum effects of almost 100%.(42) In the absence of a functional endothelium, 
the effect of 29 (EC50 = 42.1 μM) was reduced but still significant. Experimental 
pharmacological evidence ruled out the COX pathway, the participation of K+-channels, and a 
direct cholinergic action in the relaxation effect of 29. However, the involvement of the NO-
cGMP pathway was demonstrated clearly.(42) Although other mechanisms could be involved in 
the endothelium-independent relaxation, the fact that 29 was demonstrated as a well-
characterized CaM antagonist led us to postulate that its mode of action could implicate also an 
interference with CaM or the contractile proteins modulated by CaM, e.g., MLCK. Therefore, 
the effect of 29 on two Ca2+-hCaM target protein complexes [Ca2+-hCaM-PDE1A and Ca2+-
hCaM-MLCK] was examined using the fluorescent biosensor hCaM M124C-mBBr.(26) CPZ 
was also used as a control for these experiments. The results revealed that 29 and CPZ perturbed 
the Ca2+-hCaM-PDE1A and Ca2+-hCaM-MLCK complexes since quenching of the fluorescence 
was observed upon titration with both inhibitors (Figure 4); compound 29 exhibited a higher 
affinity for the complex Ca2+-hCaM-PDE1A (Kd = 0.28 μM) than for Ca2+-hCaM-MLCK (Kd = 
0.55 μM). On the other hand, as compared with 29, CPZ showed slightly less affinity for the two 
complexes (Kd = 1.1 and 0.61 μM, respectively).(43) The disruption of the complex Ca2+-hCaM-
MLCK induced by 29 could also account for its vasorelaxant effect. Moreover, the differential 
affinity of 29 and CPZ for the two h-CaM complexes could be relevant for designing specific 
drugs where a particular Ca2+-hCaM target protein complex is involved.(43) 
 
 
Figure 4. Predicted binding mode of (A) malbranchueamide (29) (green sticks) into Ca2+-hCaM-
MLCK. (B) Structural model of Ca2+-hCaM-MLCK-29. Ca2+-hCaM is represented as gray 
cartoon and MLCK in orange. Amino acids involved in the interactions are shown as cyan sticks. 
 
Polyketide-Type Compounds from Selected Fungal Species 
 
The new marine Emericella sp. strain MEXU 25379 (Trichocomaceae), isolated from the 
coral Pacifigorgia rutilia, collected in the Marietas Islands on the Mexican Pacific coast, 
biosynthesizes the prenylated xanthones 33–41 (Chart 3). Most of these secondary metabolites 
have a pyran ring fused at C-6/C-7 of the xanthone core and a prenylated chain at C-4 with 
different oxidation levels.(25, 44) When tested with the hCaM L39C-mBBr/V91C-
mBBr biosensor, all compounds but 38 were found to bind to the protein with Kd values in the 
nM range, which is unusual for CaM inhibitors.(25) Xanthones 34, 40, and 33 showed the best 
affinity to the biosensor (Kd = 3.7, 6.8, and 28.7 nM, respectively). The results revealed also that 
small structural differences of these ligands greatly affect the affinity to hCaM. Thus, comparing 
the Kd values of compounds 40 and 41 (124.7 nM), as well as those of 33 and 40, showed that 
the presence of an isoprenyl chain at C-4 and opening of the pyran ring increased the affinity for 
the protein. On the other hand, contrasting the Kd values of 34, 35 (235.1 nM), and 36 (93.0 nM) 
showed that the presence of any substituent at C-14, as in compound 35, or opening of an epoxy 
functionality, as in 36, decreased the affinity to the Ca2+-hCaM complex. Moreover, replacement 
of the OH group at C-16 for a chlorine group, as in 38 (Kd = 7.3 μM), decreased the affinity 
toward the complex. Finally, docking studies predicted all xanthones but 38 and 40 bind 
to hCaM like TFP does, having hydrogen bonds and hydrophobic interactions that stabilized the 
Ca2+-hCaM-ligand complexes.(25) 
 
Chart 3 
 
 
Other fungal compounds binding to Ca2+-hCaM in the nM range were acremoxanthone C (42) 
and acremonidin A (43) (Chart 3), which were isolated recently from the PDB culture 
of Purpureocillum lilacinum (Thom) Luangsa-ard, Houbraken, Hywel-Jones & Samson 
(Ophiocordycipitaceae), a saprobic filamentous fungus isolated from the soil and some 
insects.(28) These two xanthone–anthraquinone heterodimers bind to hCaM M124C-
mBBr with Kd values of 18.3 and 19.4 nM, respectively, 70-fold lower than that of CPZ. Docking 
analysis predicted that 42 binds to Ca2+-hCaM at a similar site to the vinblastine analogue KAR-
2, which is uncommon.(28, 45) The higher percentage of quenching and fluorescence maximum 
displacement caused by 42, when tested with hCaM T110C-mBBr, supported the unusual 
binding site predicted by the docking study. As in the case of KAR-2, compound 42 might not 
inhibit most of the modulatory properties of hCaM. The cytotoxic effects displayed 
by 42 and 43 may be related to their anti-CaM properties.(46) 
 
The next example refers to an interesting water-soluble polyketide characterized as vermelhotin 
(44) (Chart 3), which was isolated from a new endophytic fungal strain, MEXU 26343 
(Pleosporales), associated with Hintonia latiflora (Sessé et Moc. ex DC.) Bull. 
(Rubiaceae).(47) This compound undergoes an interconversion between the E/Z isomers, 
forming an equilibrium with a ratio of 1:1. The affinity of 44 (Kd = 0.25 μM) with Ca2+-hCaM in 
solution was measured using the hCaM M124C-mBBr biosensor. The docking analysis predicted 
that both the E and Z isomers interacted with Ca2+-hCaM at the same site as TFP, displaying 
mainly hydrophobic interactions with Phe92, Met109, Met124, Glu127, Ala128, and Met144 and 
one hydrogen bond with Glu127.(47) 
 
According to the Lorke test,(48) compound 44 was nontoxic to mice when given orally up to 5 
g/kg and exhibited a significant phytogrowth inhibitory effect when tested against Amaranthus 
hypochondriacus (IC50 = 141 μM vs 223 μM for Rival), Echinochloa crusgalli (IC50 = 50 μM vs 
12.28 μM for Rival), Medicago sativa (IC50 = 358 μM vs 914 μM for Rival), and Ipomea 
purpurea (IC50= 361 μM vs 202 μM for Rival). Whether or not this effect is related to its anti-
CaM action, as has been demonstrated for ophiobolin A, remains an open question. 
 
Another endophyte isolated from H. latiflora was Sporormiella minimoides S.I. Ahmed & Cain 
(Sporormiaceae) [=Preussia minimoides (S.I. Ahmed & Cain) Valldos. & Guarro]. This fungus, 
also cultured in rice, yielded several new polyketides of the corymbiferone family.(27) All 
compounds were tested as potential Ca2+-hCaM inhibitors, but only the 
naphthoquinone 45 (Chart 3) quenched significantly the extrinsic fluorescence of the hCaM 
V91C-mBBr biosensor, with a Kd value of 1.6 μM. Refined docking analysis predicted that it 
binds to Ca2+-hCaM at the classical site, displaying hydrophobic interactions with several amino 
acids.(27) 
 
Bioassay-guided fractionation of an active extract of the marine-derived fungus Aspergillus 
stromatoides Raper & Fennell (Trichocomaceae) led to the isolation of the anti-CaM 
anthraquinones emodin (46) and ω-hydroxyemodin (47) (Chart 3), along with citrinin, methyl 8-
hydroxy-6-methyl-9-oxo-9H-xanthene-1-carboxylate, and coniochaetone 
A.(49) Compounds 46 and 47 quenched the fluorescence of hCaM M124C-mBBr in a 
concentration-dependent manner with Kd values of 0.33 and 0.76 μM, respectively. Docking 
analysis revealed that both compounds bind to the same pocket of CPZ.(49) The hCaM 
inhibitory property of these compounds could be correlated with their widely described 
antineoplastic and anti-inflammatory activities, as well as their effect on several CaM-dependent 
enzymes such as mitogen-activated protein kinase (MAPK), protein kinase C (PKC), and 
MLCK.(50) 
 
From the coprophilous fungus Guanomyces polythrix M.C. González, Hanlin & Ulloa 
(Chaetomiaceae), a number of phytotoxic naphthopyranones (48–53) (Chart 3) were 
obtained.(51-53) The anti-CaM properties of these compounds have been explored using 
different procedures. More recently, their ability to quench the extrinsic fluorescence of hCaM 
M124C-AF350 was assessed. The results indicated that compounds 48–50 and 52 bind to the 
protein with Kd values at the μM level, with compounds 49 and 50 having the strongest affinities 
(Kd = 0.39 and 2.2 μM, respectively). Molecular docking analysis of all active compounds (48–
50 and 52), using a crystal structure of hCaM (Ca2+-hCaM-2TFP, PDB code 1A29), showed that 
all bind to the same site as TFP, with hydrophobic interactions stabilizing the complexes. 
 
Epipolythiodioxopiperazine and Peptides 
 
Bioassay-guided fractionation of an active organic extract of Chaetomium globosum Kunze & 
Schmidt (Chaetomiaceae), a maize pathogenic fungus, led to the separation of the 
epipolythiodioxopiperazine chaetomine (54) (Chart 4). Compound 54 binds to the hCaM 
M124C-AF350 biosensor with a Kd value of 57 nM, 11-fold higher than TFP. Molecular docking 
predicted that 54 interacted with Ca2+-hCaM in a similar manner to KAR-2 (Figure 5). 
 
Chart 4 
 
 
 
Figure 5. Predicted binding mode of (A) chaetomine (54) (blue sticks) and (B) KAR-2 (yellow 
sticks) into Ca2+-hCaM (hydrogen bonds are shown as green dashed lines). Amino acids 
involved in the interactions are shown as cyan sticks. 
 
Seven lipophilic and neutral cyclotetradepsipeptides, namely, beauverolides C (55), F (56), I 
(57), Ja (58), L (59), M (60), and N (61) (Chart 4), were obtained from Isaria fumosorosea Wize 
(Ascomycota) [syn: Paecilomyces fumosoroseus (Wize) A.H.S. Br. & G. Sm.], an 
entomopathogenic fungus isolated from the whitefly.(26) These peptides showed prominent anti-
CaM activity as revealed in testing with hCaM M124C-AF350; their Kd values ranged from 0.08 
to 3.4 μM. The most active compound, 58, was almost 10-fold more active than CPZ. It is 
noteworthy that 58 is the only compound in the series with a tryptophan moiety in its 
structure.(26) 
 
Docking of beauverolides 55–61 into Ca2+-hCaM suggested that, in all cases, they bind in the 
same pocket as CPZ. The residues involved in the interactions comprise Glu14, Ala15, Leu18, 
Phe92, Ile100, Leu105, Leu109, Glu114, Met124, Ile125, Glu127, Ala128, Phe141, and Met144. 
The binding forces in all cases were mainly hydrophobic in nature, since non-hydrogen bond 
formation was detected.(26) 
 
During the course of the investigations described above, many other secondary metabolites from 
fungi were tested as Ca2+-hCaM inhibitors, but they failed to quench the fluorescence of the 
different biosensors. These compounds included the indole alkaloid brevianamide A 
from Penicillium brevicompactum, which has been proposed as a biosynthetic precursor of the 
malbrancheamides; the polyketides mycophenolic acid, brefeldin A, citrinin, griseofulvin, and 
fimetarone A from P. brevicompactum, Curvularia pallescens, A. stromatoides, P. raistrickii, 
and Chaetomium sp., respectively; and, finally, aphidicolin, a tetracyclic diterpene 
from Nigrospora oryzae. 
 
Selected Alkaloids from Plants 
 
Berberine 
 
The isoquinoline alkaloid berberine (62) (Chart 5), isolated from various plant species, possesses 
a number of biological activities including antibacterial, anti-inflammatory, and antineoplastic 
effects.(54) Several mechanisms have been proposed to explain the potential anticancer activity 
of 62 such as direct interaction with DNA or RNA, regulation of gene expression, and 
augmentation of reactive oxygen species.(54) Recently, it was demonstrated that CaM, 
cytochrome P450 3A4, sex hormone-binding globulin, and carbonic anhydrase II are potential 
targets of 62. The investigation was initially conducted with a computational pipeline based on a 
ligand–protein inverse docking program (INVDOCK) and mining of the Connectivity MAP data. 
INVDOCK is a ligand–protein inverse docking algorithm, which could predict potential target 
proteins of a small molecule by attempting to dock it to known ligand-binding pockets of each of 
the protein entries in the PDB database. The anti-CaM property predicted for 62 was then 
confirmed with an FEA with PDE1 as reporter enzyme (IC50 = 39.7 μM). In addition, flow 
cytometric analysis revealed that the berberine-induced G1 cell cycle arrest in Bel7402 cells was 
enhanced by cotreatment with CaM inhibitors such as TFP. Western blotting data indicated 
that 62 decreased phosphorylation of CaM kinase II and blocked subsequent MEK1 activation as 
well as p27 protein degradation. These results suggested that CaM might play a crucial role in 
the induction of cell cycle arrest in cancer cells.(54) 
 
Brucine and Tetrahydropalmatine 
 
A rapid and sensitive method to detect Ca2+-CaM ligands was described by Ma and co-
workers(20) based on IF-MALDI mass spectrometry, which is a powerful tool to detect the 
formation of protein–organic compounds and protein–nucleic acids, as well as discover ligands 
in biological extracts for the screening of protein ligands. The method is based on a selective 
decrease (fading) of the ion abundance of specific ligands after the addition of the target protein, 
in this case Ca2+-CaM. Testing of berbamine (63), tetrandrine (64), papaverine (65), reserpine 
(66), brucine (67), and tetrahydropalmatine (68) (Chart 5) resulted in a relative intensity fading 
(IF) after the addition of bovine Ca2+-CaM, indicating that they bind to the protein. The relative 
IF was determined by comparison with the nonbinding drug propranolol. On the other hand, 
strychnine and piperine had either no or a weak interaction with Ca2+-CaM using the same 
procedure. Competitive experiments were also performed with the IF-MALDI mass 
spectrometry method. It is important to point out that this is the first report of the anti-CaM 
properties of alkaloids 67 and 68.(20) 
 
Chart 5 
 
 
Selected Flavonoids 
 
A few structurally related flavonoids (flavone, 3-hydroxyflavone, 6-hydroxyflavone, 7-
hydroxyflavone, chrysin, quercetin, naringenin, and 6-hydroxykaempferol 3,7-dimethyl ether) 
showed CaM inhibitory activities in the Ca2+-CaM-PDE1 assay (IC50 values from 5.2 to 102.3 
μM).(55) These flavonoids displayed also an important vasorelaxant effect, indicating that their 
mode of action could involve an anti-CaM activity or an interference with contractile proteins 
modulated by CaM, as in the case of malbrancheamide (29). 
 
Sesquiterpene Lactones 
 
The antineoplastic sesquiterpene lactones tehranolide (69) and artemisinin (70) (Chart 5), 
isolated from Artemisia diffusa Krasch. ex Poljak (Asteraceae) and other Artemisia species, 
revealed their important anti-CaM effects through the change on fluorescence emission spectra 
of the protein and CaM-mediated activation of PDE1.(56) It was found that 69 has a higher 
inhibition constant (Kd = 6.1 μM) than 70 (Kd = 10 μM). In addition, 69 significantly reduces cell 
proliferation in a time- and dose-dependent manner in K562 cells, without affecting the growth 
of peripheral lymphocytes, as indicated in a cytotoxic assay.(56) 
 
Natural Antimitotic Drugs 
 
The interaction of Ca2+-CaM with the alkaloidal antimitotic drugs vinblastine and vincristine has 
been demonstrated by using different spectroscopic techniques, including circular dichroism and 
fluorescence-based methods.(38) However, the direct effect on Ca2+-hCaM of other antimitotic 
drugs such as paclitaxel (Taxol), griseofulvin, and colchicine has not been demonstrated yet. 
When vinblastine, vincristine, and colchicine were tested with the Ca2+-Ca2+-hCaM M124C-
mBBr biosensor, they quenched, in a concentration-dependent manner, the fluorescence of the 
device (Kd = 1.7, 0.80, and 0.50 μM, respectively). On the other hand, paclitaxel and 
griseofulvin, which share the same antimitotic mechanism, including increase of microtubule 
polymerization, did not induce quenching of Ca2+-hCaM M124C-mBBr.(57, 58) The 
implications of these results remain to be determined. 
 
Concluding Remarks 
 
The recent literature concerning anti-CaM natural products has been updated in this review. In 
most cases, the activity observed correlated well with the known pharmacological properties of 
the compounds. A few inhibitors in the nanomolar potency range were detected using recently 
designed fluorescent biosensors. These tools are important technological developments and 
represent the state of the art for detecting new and potent CaM inhibitors in a very sensitive and 
specific fashion. The most active compounds were isolated from the fungal kingdom, which thus 
represent a valuable source of new and potent CaM antagonists in comparison to plant 
constituents. Therefore, these compounds represent leads for the development of new drugs as 
well as valuable research tools for understanding anti-CaM mechanisms. 
 
Notes 
 
# Adapted from a Norman R. Farnsworth Research Achievement Award address, 55th Annual 
Meeting of the American Society of Pharmacognosy, Oxford, Mississippi, August 2–6, 2014. 
 
The authors declare no competing financial interest. 
 
Dedicated to Dr. William Fenical of Scripps Institution of Oceanography, University of 
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